From In Vivo Predictive Dissolution to Virtual Bioequivalence: A GastroPlus®-Driven Framework for Generic Candesartan Cilexetil Tablets
Pharmaceuticals · 11.04.2025 · 18 (4) · 562
DOI: 10.3390/ph18040562 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 11.04.2025. Verfasst von Hao Ruan und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310014, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhejiang Basic Public Welfare Research Program, Science and Technology Project of Zhejiang Medical Products Administration.
Abstract (Originalsprache)
Background
Candesartan cilexetil, a Biopharmaceutics Classification System (BCS) II prodrug, demonstrates compromised bioavailability attributable to its limited aqueous solubility coupled with P-glycoprotein (P-gp)-mediated efflux and hepatic first-pass metabolism, thereby introducing complexities in generic drug bioequivalence assessments. With the rapid advancement of computational technologies, the integration of biorelevant dissolution methodologies with physiologically based pharmacokinetic (PBPK) modeling is emerging as a transformative paradigm in advancing bioequivalence evaluation strategies for generic drug products. This study presents a GastroPlus®-driven framework integrating in vivo predictive dissolution (IPD) and virtual bioequivalence (VBE) to evaluate the quality consistency of generic candesartan cilexetil tablets.
Methods
By developing an oral PBPK model in GastroPlus®, we established an IPD method using a phosphate-buffer-based flow-through cell dissolution apparatus. In vitro dissolution profiles of generic tablets from four manufacturers were measured and incorporated into the model to perform VBE simulations.
Results
The results demonstrated that only the product from Company A achieved virtual bioequivalence with the reference product, aligning with real-world quality consistency assessments.
Conclusions
The proposed framework exhibited robust predictive capability, bridging in vitro dissolution data to in vivo bioequivalence outcomes, thereby offering a cost-effective and efficient strategy for formulation optimization and preclinical bioequivalence evaluation of generic drugs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310014, China.
- Zhejiang Key Laboratory of Biopharmaceutical Contact Materials, NMPA Key Laboratory for Core Technology of Generic Drug Evaluation, Zhejiang Institute for Food and Drug Control, Hangzhou 310052, China.
- School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
- Zhejiang Yongning Pharmaceutical Co., Ltd., Taizhou 318020, China.
Förderung
- Zhejiang Basic Public Welfare Research Program
- Science and Technology Project of Zhejiang Medical Products Administration
Zitieren
APA
Ruan, H., Geng, X., Situ, Z., Shen, Q., Ye, T., Chen, X., & Su, W. (2025). From In Vivo Predictive Dissolution to Virtual Bioequivalence: A GastroPlus®-Driven Framework for Generic Candesartan Cilexetil Tablets. Pharmaceuticals, 18(4), 562. https://doi.org/10.3390/ph18040562
Vancouver
Ruan H, Geng X, Situ Z, Shen Q, Ye T, Chen X, et al. From In Vivo Predictive Dissolution to Virtual Bioequivalence: A GastroPlus®-Driven Framework for Generic Candesartan Cilexetil Tablets. Pharmaceuticals. 2025;18(4):562. doi:10.3390/ph18040562
BibTeX
@article{Ruan2025,
author = {Ruan, Hao and Geng, Xiaoting and Situ, Zijing and Shen, Qian and Ye, Tianjian and Chen, Xin and Su, Weike},
title = {From In Vivo Predictive Dissolution to Virtual Bioequivalence: A GastroPlus®-Driven Framework for Generic Candesartan Cilexetil Tablets},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {4},
pages = {562},
doi = {10.3390/ph18040562}
}
EUVIMED